Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
Pulse Biosciences recently reported first patient treatments in a multi-center, first-in-human feasibility study of its FDA-cleared nPulse Vybrance Percutaneous Electrode System using nanosecond ...
Pulse Biosciences (Nasdaq:PLSE) announced a new strategic alignment to focus on its nPulse cardiac catheter ablation system.
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results